Publikationen, an denen er mitarbeitet REBECA DIEZ ALARCIA (28)

2024

  1. G protein-specific mechanisms in the serotonin 5-HT2A receptor regulate psychosis-related effects and memory deficits

    Nature communications, Vol. 15, Núm. 1, pp. 4307

  2. Ligand bias and inverse agonism on 5-HT2A receptor-mediated modulation of G protein activity in post-mortem human brain

    British Journal of Pharmacology

2023

  1. Design, Synthesis, Molecular Docking, and Biological Evaluation of Novel Pimavanserin-Based Analogues as Potential Serotonin 5-HT2A Receptor Inverse Agonists

    Journal of Medicinal Chemistry, Vol. 66, Núm. 13, pp. 9057-9075

  2. Isolation and Differentiation of Neurons and Glial Cells from Olfactory Epithelium in Living Subjects

    Molecular Neurobiology, Vol. 60, Núm. 8, pp. 4472-4487

2021

  1. Adrenergic Modulation With Photochromic Ligands

    Angewandte Chemie - International Edition, Vol. 60, Núm. 7, pp. 3625-3631

  2. Characterization of dopamine D2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia

    Pharmacological Reports, Vol. 73, Núm. 4, pp. 1136-1146

  3. Correction to: Functional approaches to the study of G-protein-coupled receptors in postmortem brain tissue: [35S]GTPγS binding assays combined with immunoprecipitation (Pharmacological Reports, (2021), 73, 4, (1079-1095), 10.1007/s43440-021-00253-z)

    Pharmacological Reports

  4. Evaluación del receptor de serotonina 5-HT2A en esquizofrenia: un ejemplo de investigación traslacional basada en farmacología

    Actualidad en farmacología y terapéutica, Vol. 19, Núm. 3, pp. 154-165

  5. Functional approaches to the study of G-protein-coupled receptors in postmortem brain tissue: [35S]GTPγS binding assays combined with immunoprecipitation

    Pharmacological Reports, Vol. 73, Núm. 4, pp. 1079-1095

  6. Opposite alterations of 5­HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile

    Translational Psychiatry, Vol. 11, Núm. 1

  7. α2A- and α2C-adrenoceptor expression and functionality in postmortem prefrontal cortex of schizophrenia subjects

    European Neuropsychopharmacology, Vol. 52, pp. 3-11

2020

  1. Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Gαi1- and neutral antagonism for Gαq/11-proteins in human brain cortex

    European Neuropsychopharmacology, Vol. 36, pp. 83-89

  2. Ribosomal Protein S6 Hypofunction in Postmortem Human Brain Links mTORC1-Dependent Signaling and Schizophrenia

    Frontiers in Pharmacology, Vol. 11

2019

  1. Big Data Challenges Targeting Proteins in GPCR Signaling Pathways; Combining PTML-ChEMBL Models and [35S]GTPγS Binding Assays

    ACS Chemical Neuroscience, Vol. 10, Núm. 11, pp. 4476-4491

  2. Chronic fluoxetine reverses the effects of chronic corticosterone treatment on α2-adrenoceptors in the rat frontal cortex but not locus coeruleus

    Neuropharmacology, Vol. 158

  3. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins

    European Neuropsychopharmacology, Vol. 29, Núm. 12, pp. 1453-1463

2018

  1. Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway

    Neuropsychopharmacology, Vol. 43, Núm. 10, pp. 2028-2035

2016

  1. Biased agonism of three different cannabinoid receptor agonists in mouse brain cortex

    Frontiers in Pharmacology, Vol. 7, Núm. NOV

  2. Effect of subchronic corticosterone administration on α2-adrenoceptor functionality in rat brain: an in vivo and in vitro study

    Psychopharmacology, Vol. 233, Núm. 23-24, pp. 3861-3867

2014

  1. Diferentes propiedades farmacológicas de ketanserina y altanserina sobre los receptores 5-HT2A en cerebro humano postmortem: Interés en estudio de esquizofrenia

    Actualidad en farmacología y terapéutica, Vol. 12, Núm. 1, pp. 59-63